|

Multiple Sclerosis Clinical Trials in Orlando, FL

10 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 3<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1<1 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 3<1 mi
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyPhase 4<1 mi
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPhase 36 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Phase 26 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—6 mi
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPhase 36 mi
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisPhase 16 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPhase 39 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.